Pancreatic ductal adenocarcinoma (PDAC) · line 1 · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | None |
| ID | IND-PDAC-BORDERLINE-RESECTABLE-NEOADJ-FOLFIRINOX |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-08 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-PDAC |
| Sources | SRC-ESMO-PANCREATIC-2024 SRC-NCCN-PANCREATIC-2025 SRC-NORPACT-1-LABORI-2024 SRC-PRODIGE-24-CONROY-2018 |
Notes
GI-3 Phase C2: §17 3-phase periop indication for borderline-resectable PDAC, mirroring GI-2 C1 FLOT periop pattern. The phases[] block models neoadjuvant FOLFIRINOX × 4 → Whipple (SUR-WHIPPLE, promoted from fixture in same chunk) → adjuvant mFOLFIRINOX × 8. evidence_level: moderate + nccn_category 2A reflect consensus-extrapolation status — NORPACT-1 (the closest RCT) tested neoadjuvant FOLFIRINOX in clearly resectable (NOT BR) PDAC and did NOT show superiority; the BR-specific recommendation rests on NCCN / ESMO consensus + observational BR-cohort signals + PRODIGE-24 adjuvant rationale. Clinical sign-off should explicitly review the consensus-extrapolation framing. Engine routing from PDAC algorithm to this indication is out of C2 scope — flagged for D2 algorithm-extension chunk follow-up.
Used By
Algorithms
ALGO-PDAC-RESECTABLE-PERIOP- ALGO-PDAC-RESECTABLE-PERIOP